GT Biopharma Inc (GTBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2019 | 09-2019 | 06-2019 | 03-2019 | 12-2018 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 28 | 313 | 264 | 51 | 60 |
| TOTAL | $274 | $337 | $286 | $78 | $90 |
| Non-Current Assets | |||||
| PPE Net | N/A | N/A | N/A | 34 | 35 |
| Intangibles | 0 | 0 | 25,262 | 25,262 | 25,262 |
| Other Non-Current Assets | 122 | 145 | 159 | 165 | 12 |
| TOTAL | $122 | $145 | $25,421 | $25,461 | $25,309 |
| Total Assets | $396 | $482 | $25,707 | $25,539 | $25,399 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 13,207 | 13,143 | 12,170 | 11,297 | 10,673 |
| Accounts payable and accrued liabilities | 1,940 | 1,720 | 1,710 | 1,898 | 1,762 |
| Accrued Expenses | 4,408 | 3,732 | 2,665 | 2,136 | 1,455 |
| TOTAL | $19,706 | $18,768 | $16,731 | $15,523 | $14,029 |
| Non-Current Liabilities | |||||
| Deferred Revenues | N/A | 8 | 8 | 0 | 8 |
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $19,706 | $18,768 | $16,731 | $15,523 | $14,029 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 138 | 132 | 130 | 101 | 101 |
| Common Shares | 41 | 67 | 53 | 51 | 51 |
| Retained earnings | -567,332 | -565,862 | -535,984 | -533,195 | -528,685 |
| Other shareholders' equity | -166 | -166 | -166 | -167 | -167 |
| TOTAL | $-19,310 | $-18,286 | $8,976 | $10,016 | $11,370 |
| Total Liabilities And Equity | $396 | $482 | $25,707 | $25,539 | $25,399 |